Isomorphic Labs has unveiled its innovative artificial intelligence model, IsoDDE, which is anticipated to revolutionize the field of drug discovery. This announcement was made following a technical report dated February 10, 2026, detailing the model's capabilities. Based in London, the company asserts that IsoDDE can effectively predict protein interactions with therapeutic molecules, a significant improvement over its predecessor, AlphaFold3.
While AlphaFold3 was developed with drug discovery in mind, IsoDDE is said to surpass its performance metrics. However, the proprietary nature of IsoDDE has raised concerns among researchers pursuing open-source solutions, as the model's details remain undisclosed. Mohammed AlQuraishi, a computational biologist at Columbia University, highlighted the frustration stemming from this lack of transparency, stating that it restricts the ability of scientists to replicate its advancements.
IsoDDE reportedly excels in predicting binding affinities and drug-protein interactions, outperforming traditional physics-based methods and the open-source model Boltz-2. Max Jaderberg, president of Isomorphic Labs, described the underlying models of IsoDDE as “profoundly different” from other existing technologies but did not reveal further specifics about the algorithms or data utilized in its development. Researchers are now looking to leverage these advancements as they continue to push the boundaries in therapeutic development.